Plasmid DNA production for gene therapy and therapeutic or preventive vaccination in humans: A challenge for the pharmaceutical industry;Producción de ADN plasmídico para la terapia génica y vacunas terapéuticas o preventivas en seres humanos: Un reto para la industria farmacéutica

Biotecnologia Aplicada

Volumn 22, Issue 4, 2005, Pages 246-255

  Vázquez, Raysa ^a   Brito, José E ^a   Pérez, Mariela ^a   Silva, Ricardo ^a   Seralena, Alina ^a   Dueñas Carrera, Santiago ^a   Frontela, Maida C ^a   Herrera, Antonieta M ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

DNA vaccine; Plasmid; Preparative purification

Indexed keywords

EID: 58149128637     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, etal. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8.
2. Yankauckas MA, Morrow JE, Parker SE, Abai A, Rhodes GH, Dwarki VJ, et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol 1993;12:771-3.
3. Donnelly JJ, Martínez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 1996; 713:314-20.
4. Cardoso AI, Blixenkrone-Moller M, Fayolle J, Liu M, Buckland R, Wild TF. Immunization with plasmid DNA encoding for the measles virus hemagglutinin and nucleoprotein leads to humoral and cellmediated immunity. Virology 1996; 225:293-9.
5. Bot A, Bot S, García-Sastre A, Bona C. DNA immunization of newborn mice with a plasmid-expressing nucleoprotein of influenza virus. Viral Immunol 1996;9: 207-10.
6. Hassett DE, Zhang J, Whitton JL. Neonatal DNA immunization with a plasmid encoding an internal viral protein is effective in the presence of maternal antibodies and protects against subsequent viral challenge. J Virol 1997;71: 7881-8.
7. Tanghe A, Lefevre P, Denis O, D'Souza S, Braibant M, Lozes E, et al. Immunogenicity and protective efficacy of tuberculosis DNA vaccines encoding putative phosphate transport receptors. J Immunol 1999;162: 1113-9.
8. Chen L, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991; 88:110-4.
9. Hofland H, Huang L. Inhibition of human ovarian carcinoma cell proliferation by liposome-plasmid DNA complex. Biochem Biophys Res Com 1995;207:492-6.
10. Saito H. Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in B cell malignancy. Gene Therapy 1996;3:988-93.
11. Mor G, Klinman DM, Shapiro S, Hagiwara E, Sedegah M, Norman JA, et al. Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol 1995;155:2039-46.
12. Lowrie DB, Silva CL, Tascon RE. DNA vaccines against tuberculosis. Immunol Cell Biol 1997;75:591-4.
13. 8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infection and immunity 1998;66:1527-33.
14. Guidlines for assuring the quality of DNA vaccines (final draft). US Food and Drug Administration, Rockville, MD, USA; 1997.
15. Sambrook J, Fritsch EF, Maniatis T. Purification of closed circular DNA by equilibrium centrifugation in CsCL ethidium bromide gradients. In: Molecular cloning 1. A Laboratory Manual. 2da. ed. Cold Sprig Harbor Laboratory Press; 1989.p.42-7.
16. Sambrook J, Fritsch EF, Maniatis T. Purification of plasmid DNA by precipitation with polyethylene glycol. In: Molecular cloning 1. A Laboratory Manual. 2da. ed. Cold Sprig Harbor Laboratory Press 1989. p.40-2.
17. Herrera AM, López-Campistrous AE, Román C, Sández B, Hayes O, Hechavarría M, et al. Use of plasmid DNA purified by PEG precipitation for in vivo transfection in mice. Minerva Biotec 1997;9:25-8.
18. Catarota S, Bratt G, Nordlund S, Hinkula J, Leandorason A, Sandstrom E, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998;351:1320-5.
19. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R. Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999;17:2826-9.
20. Ayazi Shamlou, P. Scalable processes for the manufacture of therapeutic quantities of plasmid DNA. Biotechnol & Appl Biochemistry;2003.
21. DoHHS. Points to consider in the characterization of cell lines used to produce biologicals;1993.
22. Lahijani R, Hulley G, Soriano G, Horn NA, Marquet M. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum Gene Ther 1996;16:1971-80.
23. Dueñas-Carrera S, Álvarez-Lajonchere L, Álvarez- Obregón JC, Pérez A, Acosta-Rivero N, Vázquez DM, Martínez G, Viña A, Pichardo D, Morales J. Enhancement of the immune response generated against the hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids. Biotechnol Appl Biochem 2002;35:205-12.
24. Inchauspe G, Feinstone S: Development of a hepatitis C virus vaccine. Clin Liver Dis 2003;7:243-59.
25. Ojalvo AG, Seralena A, Vázquez R, Montequín JF, Vispo NS, Silva R, ALdama A, Puchades Y, Sorell LT, López-Saura P, Alfonso MA, Simón R, Ali A, Seuc A, Herrera L. Therapeutic angiogenesis following intramuscular gene transfer of vascular endothelial growth factor 121 in a dog model of hindlimb ischemia. Electronic J Biotechnol 2003;6:208-22.
26. Kendall D, Lye GJ, Levy MS. Purification of plasmid DNA by an Integrated Operation Comprising Tangential Flow Filtration and Nitrocellulose Adsorption. Biotechnology and Bioengineering 2002;79(7):817-22.
27. Lin-Chao S, Chen W, Wong T. High copy number of the pUC plasmid results from a Rom/ Rop-suppressible point mu-tation in RNA II. Mol Microbiol 1992;6: 3385-93.
28. Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucl Acids Res 1979; 7:1513-23.
29. Horn NA, Meek JA, Budahazi G, Marquet M. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther 1995;6:565-73.
30. Ferreira GN, Cabral JM, Prazeres DM. Development of process flow sheets for the purification of supercoiled plasmids for gene therapy applications. Biotechnology Prog 1999;4:725-31.
31. Prazeres DM, Schluep T, Cooney C. Preparative purification of supercoiled plasmid DNA using anion-exchange chromatography. J Chromatogr A 1998; 806:31-45.
32. Braas G, Searle P, Slater N, Lyddiatt A. Strategies for the isolation and purification of retroviral vectors for gene therapy. Bioseparation 1996;6:211-28.
33. Caplen NJ, Gao X, Hayes P, Elaswa-rapu R, Fisher G, Kinrade E, et al. Gene therapy for cystic fibrosis in human by liposome-mediated DNA transfer: the pro-duction of resources and the regulatory process 1994;1:139-47.
34. Sambrook J, et al. Molecular Cloning: A laboratory Handbook, CSH Press;1989.
35. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bi-cinchoninic acid. Anal Biochem 1985; 150:76-85.
36. Marquet M, Horn NA, Meek JA. Process development for the manufacture of plasmid DNA vectors for use in gene therapy. Biopharm 1995;8:26-37.
37. Lahijani R, Duhon M, Lusby E, Betita H, Marquet M. Quantitation of host cell DNA contaminate in pharmaceutical-grade plasmid DNA using competitive polymerase chain reaction and enzyme-linked immunosorbent assay. Hum Gene Ther 1998; 9:1173-80.
38. Weintraub H, Cheng PF, Conrad K. Expression of transfected DNA depends on DNA topology. Cell 1986;46:115-22.